COMMUNIQUÉS West-GlobeNewswire

À l'occasion de l'assemblée générale annuelle de l'American Society of Gene and Cell Therapy, Abeona Therapeutics présentera des données pour ABO-401 relatives à la fibrose kystique et aux troubles rétiniens
16/04/2019
De nouvelles données facilitant les demandes d'investigation sur un nouveau médicament pour l'ABO-202 dans le cas de la maladie CLN1 seront également mises en avant NEW YORK et CLEVELAND, 16 avr. 2019 (GLOBE NEWSWIRE [...]
BioSig Completes Successful Patient Cases at Greenville Memorial Hospital
16/04/2019
Second Center to Report Positive Clinical Experience with PURE EP(tm) System Santa Monica, CA, April 16, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a [...]
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019
16/04/2019
CAMPBELL, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019 after the market close on [...]
Aleafia Health to add 50,000 kg Extraction Capacity at Paris, ON Facility
16/04/2019
Company Expecting to Complete Phase II Expansion in Q3 2019 TORONTO, April 16, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“ Aleafia Health ” or the “ Company ”) will add 50,000 kg [...]
Kamada announces FDA acceptance of Inhaled AAT program path forward
16/04/2019
Company intends to submit an IND to the FDA and a CTA to the EMA, and expects to initiate the Inhaled AAT Phase 3 pivotal study during the second half of 2019 REHOVOT, Israel, April 16, 2019 (GLOBE NEWSWIRE) -- Kamada [...]
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
16/04/2019
Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing [...]
EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
16/04/2019
Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of DEXYCU ™ to be presented at the 2019 American [...]
CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies
16/04/2019
PD-L1 Pathway Now Covered as New Patent Complements the mRNA/Anti-PD-1 Antibodies Combination Patent Granted in July 2017 TÜBINGEN, Germany and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated [...]
Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates
16/04/2019
RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers and data [...]
Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy
16/04/2019
-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to be highlighted in poster presentation- BASEL [...]
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
16/04/2019
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug [...]
IRADIMED CORPORATION to Hold 2019 First Quarter Financial Results Conference Call on April 30th
16/04/2019
WINTER SPRINGS, Fla., April 16, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 first quarter financial results before the market opens on Tuesday, [...]
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville
16/04/2019
Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed Teva to Continue to be Exclusive Marketing Partner of Verapamil SR ® Capsules with Same Revenue Economics as the [...]
Taconic Biosciences lance TruBIOME ™ en vue de créer des modèles animaux avec des profils de microbiome personnalisés
16/04/2019
RENSSELAER, N.Y., 16 avr. 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, leader mondial des solutions de modèles de rongeurs génétiquement modifiés, annonce le lancement de TruBIOME TM , une solution unique en son genre [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019
16/04/2019
Company Announcement Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 16, 2019 – Genmab A/ [...]
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
16/04/2019
GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the [...]
FDA Agrees to Rolling Review of Mesoblast’s Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease
16/04/2019
NEW YORK and MELBOURNE, Australia, April 16, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in cellular medicines for inflammatory diseases, announced today that the United States Food [...]
ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
16/04/2019
New data include secondary endpoint analyses of clinical responder rates at Day 7, End of Treatment, and Test of Cure, and pre-specified analyses of the clinical responder rates by final diagnosis at Day 14 New MRSA [...]
Corrections to the Latvian version of the news about 3 month results - corrections made only in the list of countries in the table: Unconsolidated sales – March and 3 months
16/04/2019
Corrections have been made only to the Latvian version of the news. Corrections made only in the list of the countries, mentioned in the tables: Unconsolidated sales - March and 3 months. The textual information didn't [...]

Pages